Ranibizumab for Macular Edema Due to Retinal Vein Occlusions: Implication of VEGF as a Critical Stimulator
Peter A. Campochiaro,Gulnar Hafiz,Syed Mahmood Shah,Quan Dong Nguyen,Howard S. Ying,Diana V. Do,Edward Quinlan,Ingrid Zimmer-Galler,Julia A. Haller,Sharon D. Solomon,Jennifer U. Sung,Yasmin Hadi,Kashif A. Janjua,Nida Jawed,David F. Choy,Joseph R. Arron +15 more
TLDR
Data indicate that excess production of VEGF in the retinas of patients with CRVO or BRVO is a major contributor to macular edema and suggest that additional studies investigating the efficacy of intraocular injections of ranibizumab are needed.About:
This article is published in Molecular Therapy.The article was published on 2008-04-01 and is currently open access. It has received 290 citations till now. The article focuses on the topics: Macular edema & Branch retinal vein occlusion.read more
Citations
More filters
Journal Article
Optical Coherence Tomography of the Human Retina
Michael R. Hee,Joseph A. Izatt,Eric A. Swanson,David Huang,Joel S. Schuman,Charles P. Lin,Carmen A. Puliafito,James G. Fujimoto +7 more
TL;DR: In this article, optical coherence tomography is used for high-resolution, noninvasive imaging of the human retina, including the macula and optic nerve head in normal human subjects.
Journal ArticleDOI
Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study.
David M. Brown,Peter A. Campochiaro,Rishi P. Singh,Zhengrong Li,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid improvement in 6-month visual acuity and macular edema following CRVO, with low rates of ocular and nonocular safety events.
Journal ArticleDOI
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion.
Julia A. Haller,Francesco Bandello,Rubens Belfort,Mark S. Blumenkranz,Mark C Gillies,Jeffrey S. Heier,Anat Loewenstein,Young-Hee Yoon,Marie-Louise Jacques,Jenny Jiao,Xiao-yan Li,Scott M. Whitcup +11 more
TL;DR: In this paper, the safety and efficacy of dexamethasone intravitreal implant (DEX implant; OZURDEX, Allergan, Inc., Irvine, CA) compared with sham in eyes with vision loss due to macular edema (ME) associated with BRVO or central retinal vein occlusion (CRVO).
Journal ArticleDOI
Ranibizumab for Macular Edema following Branch Retinal Vein Occlusion
Peter A. Campochiaro,Jeffrey S. Heier,Leonard Feiner,Sarah Gray,Namrata Saroj,Amy Chen Rundle,Wendy Yee Murahashi,Roman G. Rubio +7 more
TL;DR: Intraocular injections of 0.3 mg or 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO with low rates of ocular and nonocular safety events and no new safety events were identified in patients with BRVO.
Journal ArticleDOI
Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study.
David M. Brown,Peter A. Campochiaro,Robert B. Bhisitkul,Allen C. Ho,Sarah Gray,Namrata Saroj,Anthony P. Adamis,Roman G. Rubio,Wendy Yee Murahashi +8 more
TL;DR: Intraocular injections of ranibizumab provide an effective treatment for macular edema after central retinal vein occlusion, with low rates of ocular and nonocular safety events.
References
More filters
Journal ArticleDOI
Optical coherence tomography
David Huang,Eric A. Swanson,Charles P. Lin,Joel S. Schuman,William G. Stinson,Warren Chang,Michael R. Hee,Thomas J. Flotte,Kenton W. Gregory,Carmen A. Puliafito,James G. Fujimoto +10 more
TL;DR: OCT as discussed by the authors uses low-coherence interferometry to produce a two-dimensional image of optical scattering from internal tissue microstructures in a way analogous to ultrasonic pulse-echo imaging.
Journal ArticleDOI
Ranibizumab for Neovascular Age-Related Macular Degeneration
Philip J. Rosenfeld,David M. Brown,Jeffrey S. Heier,David S. Boyer,Peter K. Kaiser,Carol Chung,Robert Y. Kim +6 more
TL;DR: Intravitreal administration of ranibizumab for 2 years prevented vision loss and improved mean visual acuity, with low rates of serious adverse events, in patients with minimally classic or occult (with no classic lesions) choroidal neovascularization secondary to age-related macular degeneration.
Journal ArticleDOI
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
David M. Brown,Peter K. Kaiser,Mark Michels,Gisèle Soubrane,Jeffrey S. Heier,Robert Y. Kim,Judy P. Sy,Susan Schneider +7 more
TL;DR: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events and treatment improved visual acuity on average at 1 year.
Journal ArticleDOI
Optical Coherence Tomography of the Human Retina
Michael R. Hee,Joseph A. Izatt,Eric A. Swanson,David Huang,Joel S. Schuman,Charles P. Lin,Carmen A. Puliafito,James G. Fujimoto +7 more
TL;DR: In this paper, optical coherence tomography is used for high-resolution, noninvasive imaging of the human retina, including the macula and optic nerve head in normal human subjects.
Journal ArticleDOI
Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
TL;DR: Ranibizumab represents a novel therapy that, for the first time, appears to have the potential to enable many AMD patients to obtain a meaningful and sustained gain of vision.